These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25765417)

  • 1. Re: Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
    Goldfarb DA
    J Urol; 2015 Mar; 193(3):950. PubMed ID: 25765417
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
    Kirk AD; Guasch A; Xu H; Cheeseman J; Mead SI; Ghali A; Mehta AK; Wu D; Gebel H; Bray R; Horan J; Kean LS; Larsen CP; Pearson TC
    Am J Transplant; 2014 May; 14(5):1142-51. PubMed ID: 24684552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients.
    Del Bello A; Marion O; Milongo D; Rostaing L; Kamar N
    Expert Rev Clin Pharmacol; 2016; 9(2):215-27. PubMed ID: 26691282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belatacept treatment for two yr after liver transplantation is not associated with operational tolerance.
    Schwarz C; Rasoul-Rockenschaub S; Soliman T; Berlakovich GA; Steininger R; Mühlbacher F; Wekerle T
    Clin Transplant; 2015 Jan; 29(1):85-9. PubMed ID: 25377272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year outcomes of belatacept studies; reason to be optimistic?
    van den Hoogen MW; Pipeleers L
    Am J Transplant; 2012 Aug; 12(8):2259; discussion 2260. PubMed ID: 22758790
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune minimization strategies in renal transplantation.
    Brar JE; Nader ND
    Immunol Invest; 2014; 43(8):807-18. PubMed ID: 25296235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunosuppressive treatments: mechanisms of action and clinical use].
    Thervet E; Zuber J; Sberro R; Canaud G; Anglicheau D; Snanoudj R; Mamzer-Bruneel MF; Martinez F; Legendre C
    Nephrol Ther; 2011 Dec; 7(7):566-81. PubMed ID: 21273149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to improve long-term outcomes after renal transplantation.
    Pascual M; Theruvath T; Kawai T; Tolkoff-Rubin N; Cosimi AB
    N Engl J Med; 2002 Feb; 346(8):580-90. PubMed ID: 11856798
    [No Abstract]   [Full Text] [Related]  

  • 10. Renal Transplantation in HIV-positive Renal Transplant Recipients: Experience at the Mannheim University Hospital.
    Haas J; Singer T; Nowak K; Brust J; Göttmann U; Schnülle P; Krüger B; Krämer BK; Benck U
    Transplant Proc; 2015 Nov; 47(9):2791-4. PubMed ID: 26680097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
    Charpentier B
    Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing the regimen.
    Chapman JR
    Nephrol Dial Transplant; 1995; 10 Suppl 1():51-7. PubMed ID: 7617282
    [No Abstract]   [Full Text] [Related]  

  • 13. Co-stimulation Blockade Plus T-Cell Depletion in Transplant Patients: Towards a Steroid- and Calcineurin Inhibitor-Free Future?
    Herr F; Brunel M; Roders N; Durrbach A
    Drugs; 2016 Nov; 76(17):1589-1600. PubMed ID: 27785759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belatacept: the promises and challenges of belatacept and costimulatory blockade.
    Kaplan B
    Am J Transplant; 2010 Mar; 10(3):441-2. PubMed ID: 20415895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to belatacept-based immunosuppression therapy in renal transplant patients.
    Paz M; Roberti J; Mos F; Cicora F
    Transplant Proc; 2014 Nov; 46(9):2987-90. PubMed ID: 25420807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early conversion to belatacept after renal transplantation.
    Nair V; Liriano-Ward L; Kent R; Huprikar S; Rana M; Florman SS; Delaney VB; Menon MC; Sehgal V; Miko L; Khaim R; Benvenisty A; Lerner S; Arvelakis A; Wadhera V; Ames S; Shapiro R
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28267882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belatacept utilization recommendations: an expert position.
    Grinyó JM; Budde K; Citterio F; Charpentier B
    Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belatacept (Nulojix) for prevention of renal transplant rejection.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):98-9. PubMed ID: 22173428
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.